Effective ovarian cancer treatment is underused, US study findsBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4291 (Published 06 August 2015) Cite this as: BMJ 2015;351:h4291
- Michael McCarthy
Six years after the US National Cancer Institute issued a special clinical announcement encouraging the use of intraperitoneal and intravenous chemotherapy for ovarian cancer, less than half of eligible women were being treated with it, a new study has found.1
The institute issued the recommendation in 2006 after a randomized trial by the Gynecologic Oncology Group, the GOG-172 trial, showed that, when compared with intravenous chemotherapy alone, intraperitoneal and intravenous chemotherapy was associated with an improvement of 16 months in median overall survival among women with optimally …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial